Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Identification of G-Quadruplex-Binding Inhibitors of Myc Expression through Affinity Selection-Mass Spectrometry.

Flusberg DA, Rizvi NF, Kutilek V, Andrews C, Saradjian P, Chamberlin C, Curran P, Swalm B, Kattar S, Smith GF, Dandliker P, Nickbarg EB, O'Neil J.

SLAS Discov. 2019 Feb;24(2):142-157. doi: 10.1177/2472555218796656. Epub 2018 Sep 11.

PMID:
30204533
2.

Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry.

Rizvi NF, Howe JA, Nahvi A, Klein DJ, Fischmann TO, Kim HY, McCoy MA, Walker SS, Hruza A, Richards MP, Chamberlin C, Saradjian P, Butko MT, Mercado G, Burchard J, Strickland C, Dandliker PJ, Smith GF, Nickbarg EB.

ACS Chem Biol. 2018 Mar 16;13(3):820-831. doi: 10.1021/acschembio.7b01013. Epub 2018 Feb 14.

PMID:
29412640
3.

RNA as a small molecule druggable target.

Rizvi NF, Smith GF.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5083-5088. doi: 10.1016/j.bmcl.2017.10.052. Epub 2017 Oct 23. Review.

PMID:
29097169
4.

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.

Smith GF, Altman MD, Andresen B, Baker J, Brubaker JD, Chen H, Chen Y, Childers M, Donofrio A, Ferguson H, Fischer C, Fischmann TO, Gibeau C, Hicks A, Jin S, Kattar S, Kleinschek MA, Leccese E, Lesburg C, Li C, Lim J, Liu D, Maclean JKF, Mansoor F, Moy LY, Mulrooney EF, Necheva AS, Presland J, Rakhilina L, Yang R, Torres L, Zhang-Hoover J, Northrup A.

Bioorg Med Chem Lett. 2017 Jun 15;27(12):2721-2726. doi: 10.1016/j.bmcl.2017.04.050. Epub 2017 Apr 18.

PMID:
28501511
5.

Understanding and monitoring the consequences of human impacts on intraspecific variation.

Mimura M, Yahara T, Faith DP, Vázquez-Domínguez E, Colautti RI, Araki H, Javadi F, Núñez-Farfán J, Mori AS, Zhou S, Hollingsworth PM, Neaves LE, Fukano Y, Smith GF, Sato YI, Tachida H, Hendry AP.

Evol Appl. 2016 Nov 22;10(2):121-139. doi: 10.1111/eva.12436. eCollection 2017 Feb. Review.

6.

Synthesis of Cyclic Peptidomimetics via a Pd-Catalyzed Macroamination Reaction.

Hopkins BA, Smith GF, Sciammetta N.

Org Lett. 2016 Aug 19;18(16):4072-5. doi: 10.1021/acs.orglett.6b01961. Epub 2016 Aug 10.

PMID:
27508926
7.

Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications.

Lim J, Altman MD, Baker J, Brubaker JD, Chen H, Chen Y, Kleinschek MA, Li C, Liu D, Maclean JK, Mulrooney EF, Presland J, Rakhilina L, Smith GF, Yang R.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5384-8. doi: 10.1016/j.bmcl.2015.09.028. Epub 2015 Sep 11.

PMID:
26403930
8.

Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.

Lim J, Altman MD, Baker J, Brubaker JD, Chen H, Chen Y, Fischmann T, Gibeau C, Kleinschek MA, Leccese E, Lesburg C, Maclean JK, Moy LY, Mulrooney EF, Presland J, Rakhilina L, Smith GF, Steinhuebel D, Yang R.

ACS Med Chem Lett. 2015 Apr 20;6(6):683-8. doi: 10.1021/acsmedchemlett.5b00107. eCollection 2015 Jun 11.

9.

Evolutionary history and leaf succulence as explanations for medicinal use in aloes and the global popularity of Aloe vera.

Grace OM, Buerki S, Symonds MR, Forest F, van Wyk AE, Smith GF, Klopper RR, Bjorå CS, Neale S, Demissew S, Simmonds MS, Rønsted N.

BMC Evol Biol. 2015 Feb 26;15:29. doi: 10.1186/s12862-015-0291-7.

10.

Watercraft and watersport injuries in children: trauma mechanisms and proposed prevention strategies.

Keijzer R, Smith GF, Georgeson KE, Muensterer OJ.

J Pediatr Surg. 2013 Aug;48(8):1757-61. doi: 10.1016/j.jpedsurg.2013.03.055.

PMID:
23932618
11.
12.

Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).

Masood MA, Selby MD, Bell AS, Mansfield AC, Gardner M, Smith GF, Lane C, Kenyon-Edwards H, Osborne R, Jones RM, Liu WL, Brown CD, Clarke N, Perrucio F, Mowbray CE.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6591-5. doi: 10.1016/j.bmcl.2011.07.114. Epub 2011 Aug 27.

PMID:
21955944
13.

Extinction risk and diversification are linked in a plant biodiversity hotspot.

Davies TJ, Smith GF, Bellstedt DU, Boatwright JS, Bytebier B, Cowling RM, Forest F, Harmon LJ, Muasya AM, Schrire BD, Steenkamp Y, van der Bank M, Savolainen V.

PLoS Biol. 2011 May;9(5):e1000620. doi: 10.1371/journal.pbio.1000620. Epub 2011 May 24.

14.

Designing drugs to avoid toxicity.

Smith GF.

Prog Med Chem. 2011;50:1-47. doi: 10.1016/B978-0-12-381290-2.00001-X. No abstract available.

PMID:
21315927
15.

Use of laparoscopy in the management of pediatric abdominal trauma.

Marwan A, Harmon CM, Georgeson KE, Smith GF, Muensterer OJ.

J Trauma. 2010 Oct;69(4):761-4. doi: 10.1097/TA.0b013e3181c81d97.

PMID:
20173653
16.

The role of the primary care physician during the active treatment phase.

Smith GF, Toonen TR.

Prim Care. 2009 Dec;36(4):685-702. doi: 10.1016/j.pop.2009.07.001. Review.

PMID:
19913182
17.

Coronary artery fistula: a case series with review of the literature.

Raju MG, Goyal SK, Punnam SR, Shah DO, Smith GF, Abela GS.

J Cardiol. 2009 Jun;53(3):467-72. doi: 10.1016/j.jjcc.2008.09.009. Epub 2008 Nov 20.

18.

Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design.

Smith GF.

Prog Med Chem. 2009;48:1-29. Review. No abstract available.

PMID:
21544956
19.

Therapeutic uses of Aloe L. (Asphodelaceae) in southern Africa.

Grace OM, Simmonds MS, Smith GF, van Wyk AE.

J Ethnopharmacol. 2008 Oct 28;119(3):604-14. doi: 10.1016/j.jep.2008.07.002. Epub 2008 Jul 16. Review.

PMID:
18682283
20.

Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.

Franciskovich JB, Masters JJ, Weber WW, Klimkowski VJ, Chouinard M, Sipes PR, Johnson LM, Snyder DW, Chastain MK, Craft TJ, Towner RD, Gifford-Moore DS, Froelich LL, Smallwood JK, Foster RS, Smith GF, Liebeschuetz JW, Murray CW, Young SC.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6910-3. Epub 2007 Oct 24.

PMID:
17976987
21.

D-phenylglycinol-derived non-covalent factor Xa inhibitors: effect of non-peptidic S4 linkage elements on affinity and anticoagulant activity.

Klimkowski VJ, Watson BM, Wiley MR, Liebeschuetz J, Franciskovich JB, Marimuthu J, Bastian JA, Sall DJ, Smallwood JK, Chirgadze NY, Smith GF, Foster RS, Craft T, Sipes P, Chastain M, Sheehan SM.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5801-5. Epub 2007 Aug 28.

PMID:
17881231
22.

Anthranilamide inhibitors of factor Xa.

Mendel D, Marquart AL, Joseph S, Waid P, Yee YK, Tebbe AL, Ratz AM, Herron DK, Goodson T, Masters JJ, Franciskovich JB, Tinsley JM, Wiley MR, Weir LC, Kyle JA, Klimkowski VJ, Smith GF, Towner RD, Froelich LL, Buben J, Craft TJ.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4832-6. Epub 2007 Jun 20.

PMID:
17624775
23.

Primary care of the patient with cancer.

Smith GF, Toonen TR.

Am Fam Physician. 2007 Apr 15;75(8):1207-14. Review.

24.

Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain.

Owen DR, Dodd PG, Gayton S, Greener BS, Harbottle GW, Mantell SJ, Maw GN, Osborne SA, Rees H, Ringer TJ, Rodriguez-Lens M, Smith GF.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90. Epub 2006 Oct 11.

PMID:
17064898
25.

The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies.

Eastwood BJ, Farmen MW, Iversen PW, Craft TJ, Smallwood JK, Garbison KE, Delapp NW, Smith GF.

J Biomol Screen. 2006 Apr;11(3):253-61. Epub 2006 Feb 20.

PMID:
16490778
26.

Investigation of factor Xa inhibitors containing non-amidine S1 elements.

Franciskovich JB, Masters JJ, Tinsley JM, Craft TJ, Froelich LL, Gifford-Moore DS, Klimkowski VJ, Smallwood JK, Smith GF, Smith T, Towner RR, Weir LC, Wiley MR.

Bioorg Med Chem Lett. 2005 Nov 1;15(21):4838-41.

PMID:
16140530
27.

A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor Xa inhibitors.

Sheehan SM, Masters JJ, Wiley MR, Young SC, Liebeschuetz JW, Jones SD, Murray CW, Franciskovich JB, Engel DB, Weber WW, Marimuthu J, Kyle JA, Smallwood JK, Farmen MW, Smith GF.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2255-9.

PMID:
12824013
28.

The price of collecting life.

Smith GF, Steenkamp Y, Klopper RR, Siebert SJ, Arnold TH.

Nature. 2003 Mar 27;422(6930):375-6. No abstract available.

PMID:
12660755
29.

The application of non-combinatorial chemistry to lead discovery.

Everett J, Gardner M, Pullen F, Smith GF, Snarey M, Terrett N.

Drug Discov Today. 2001 Aug 1;6(15):779-785.

PMID:
11470586
30.

Effect of LY287045, a thrombin/trypsin inhibitor, on thrombin and trypsin-induced aortic contraction and relaxation.

Bhattacharya A, Smith GF, Cohen ML.

J Pharmacol Exp Ther. 2001 May;297(2):573-81.

PMID:
11303045
31.

1,2-Disubstituted indole, azaindole and benzimidazole derivatives possessing amine moiety: a novel series of thrombin inhibitors.

Takeuchi K, Bastian JA, Gifford-Moore DS, Harper RW, Miller SC, Mullaney JT, Sall DJ, Smith GF, Zhang M, Fisher MJ.

Bioorg Med Chem Lett. 2000 Oct 16;10(20):2347-51.

PMID:
11055353
32.

Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. Part 6: further focus on the contracted C4'-side chain analogues.

Takeuchi K, Kohn TJ, Harper RW, Lin HS, Gifford-Moore DS, Richett ME, Sall DJ, Smith GF, Zhang M.

Bioorg Med Chem Lett. 2000 Jun 5;10(11):1199-202.

PMID:
10866380
33.

Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity.

Masters JJ, Franciskovich JB, Tinsley JM, Campbell C, Campbell JB, Craft TJ, Froelich LL, Gifford-Moore DS, Hay LA, Herron DK, Klimkowski VJ, Kurz KD, Metz JT, Ratz AM, Shuman RT, Smith GF, Smith T, Towner RD, Wiley MR, Wilson A, Yee YK.

J Med Chem. 2000 Jun 1;43(11):2087-92. No abstract available.

PMID:
10841787
34.
35.

Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.

Wiley MR, Weir LC, Briggs S, Bryan NA, Buben J, Campbell C, Chirgadze NY, Conrad RC, Craft TJ, Ficorilli JV, Franciskovich JB, Froelich LL, Gifford-Moore DS, Goodson T Jr, Herron DK, Klimkowski VJ, Kurz KD, Kyle JA, Masters JJ, Ratz AM, Milot G, Shuman RT, Smith T, Smith GF, Tebbe AL, Tinsley JM.

J Med Chem. 2000 Mar 9;43(5):883-99.

PMID:
10715155
36.

N(2)-Aroylanthranilamide inhibitors of human factor Xa.

Yee YK, Tebbe AL, Linebarger JH, Beight DW, Craft TJ, Gifford-Moore D, Goodson T Jr, Herron DK, Klimkowski VJ, Kyle JA, Sawyer JS, Smith GF, Tinsley JM, Towner RD, Weir L, Wiley MR.

J Med Chem. 2000 Mar 9;43(5):873-82.

PMID:
10715154
37.

1,2-Dibenzamidobenzene inhibitors of human factor Xa.

Herron DK, Goodson T Jr, Wiley MR, Weir LC, Kyle JA, Yee YK, Tebbe AL, Tinsley JM, Mendel D, Masters JJ, Franciskovich JB, Sawyer JS, Beight DW, Ratz AM, Milot G, Hall SE, Klimkowski VJ, Wikel JH, Eastwood BJ, Towner RD, Gifford-Moore DS, Craft TJ, Smith GF.

J Med Chem. 2000 Mar 9;43(5):859-72.

PMID:
10715153
38.

Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy, and pharmacokinetic properties of modified C-3 side chain derivatives.

Sall DJ, Bailey DL, Bastian JA, Buben JA, Chirgadze NY, Clemens-Smith AC, Denney ML, Fisher MJ, Giera DD, Gifford-Moore DS, Harper RW, Johnson LM, Klimkowski VJ, Kohn TJ, Lin HS, McCowan JR, Palkowitz AD, Richett ME, Smith GF, Snyder DW, Takeuchi K, Toth JE, Zhang M.

J Med Chem. 2000 Feb 24;43(4):649-63.

PMID:
10691691
39.

The design of potent, selective, non-covalent, peptide thrombin inhibitors utilizing imidazole as a S1 binding element.

Wiley MR, Weir LC, Briggs SL, Chirgadze NY, Clawson D, Gifford-Moore DS, Schacht AL, Smith GF, Vasudevan V, Zornes LL, Klimkowski VJ.

Bioorg Med Chem Lett. 1999 Sep 20;9(18):2767-72.

PMID:
10509932
40.

Applications of combinatorial chemistry to drug design and development.

Edwards PJ, Gardner M, Klute W, Smith GF, Terrett NK.

Curr Opin Drug Discov Devel. 1999 Jul;2(4):321-31.

PMID:
19649960
41.

Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Sidechain optimization and demonstration of in vivo efficacy.

Zhang M, Bailey DL, Bastian JA, Briggs SL, Chirgadze NY, Clawson DK, Denney ML, Gifford-Moore DS, Harper RW, Johnson LM, Klimkowski VJ, Kohn TJ, Lin HS, McCowan JR, Richett ME, Sall DJ, Smith AJ, Smith GF, Snyder DW, Takeuchi K, Utterback BG, Yan SC.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):775-80.

PMID:
10201846
42.

Dibasic benzo[B]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 4. SAR studies on the conformationally restricted C3-side chain of hydroxybenzo[B]thiophenes.

Takeuchi K, Kohn TJ, Sall DJ, Denney ML, McCowan JR, Smith GF, Gifford-Moore DS.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):759-64.

PMID:
10201843
43.

Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 3. Enhancing activity by imposing conformational restriction in the C-4" side chain.

Bastian JA, Chirgadze N, Denney ML, Gifford-Moore DS, Sall DJ, Smith GF, Wikel JH.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):363-8.

PMID:
10091685
44.

Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 2. Exploring interactions at the proximal (S2) binding site.

Sall DJ, Briggs SL, Chirgadze NY, Clawson DK, Gifford-Moore DS, Klimkowski VJ, McCowan JR, Smith GF, Wikel JH.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2527-32.

PMID:
9873574
45.

Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure-activity relationships, and binding orientation.

Sall DJ, Bastian JA, Briggs SL, Buben JA, Chirgadze NY, Clawson DK, Denney ML, Giera DD, Gifford-Moore DS, Harper RW, Hauser KL, Klimkowski VJ, Kohn TJ, Lin HS, McCowan JR, Palkowitz AD, Smith GF, Takeuchi K, Thrasher KJ, Tinsley JM, Utterback BG, Yan SC, Zhang M.

J Med Chem. 1997 Oct 24;40(22):3489-93. No abstract available.

PMID:
9357512
46.

The crystal structure of human alpha-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor.

Chirgadze NY, Sall DJ, Klimkowski VJ, Clawson DK, Briggs SL, Hermann R, Smith GF, Gifford-Moore DS, Wery JP.

Protein Sci. 1997 Jul;6(7):1412-7.

47.

Pediatric cervical spine injury: a three-year experience.

Givens TG, Polley KA, Smith GF, Hardin WD Jr.

J Trauma. 1996 Aug;41(2):310-4.

PMID:
8760542
48.

Physicians can achieve high hopes for managed care.

Smith GF.

Tex Med. 1996 Apr;92(4):7-8. No abstract available.

PMID:
8901059
49.

A family of arginal thrombin inhibitors related to efegatran.

Smith GF, Shuman RT, Craft TJ, Gifford DS, Kurz KD, Jones ND, Chirgadze N, Hermann RB, Coffman WJ, Sandusky GE, Roberts E, Jackson CV.

Semin Thromb Hemost. 1996;22(2):173-83.

PMID:
8807715
50.

Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitutions.

Shuman RT, Rothenberger RB, Campbell CS, Smith GF, Gifford-Moore DS, Paschal JW, Gesellchen PD.

J Med Chem. 1995 Oct 27;38(22):4446-53.

PMID:
7473571

Supplemental Content

Loading ...
Support Center